Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Companies Reimbursement

EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus

Executive Summary

By selling off its critical care business, EUSA Pharma gets needed funds and freedom to fully focus on oncology and rare diseases, its CEO tells Scrip.

You may also be interested in...



Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Table

View full table

Topics

Related Companies

Tags:
Deals Companies Reimbursement
Latest Headlines

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

See All
UsernamePublicRestriction

Register

SC123403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By